<?xml version="1.0" encoding="UTF-8"?>
<ref id="B11-viruses-12-00177">
 <label>11.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mikulski</surname>
    <given-names>S.M.</given-names>
   </name>
   <name>
    <surname>Costanzi</surname>
    <given-names>J.J.</given-names>
   </name>
   <name>
    <surname>Vogelzang</surname>
    <given-names>N.J.</given-names>
   </name>
   <name>
    <surname>McCachren</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Taub</surname>
    <given-names>R.N.</given-names>
   </name>
   <name>
    <surname>Chun</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Mittelman</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Panella</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Puccio</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Fine</surname>
    <given-names>R.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma</article-title>
  <source>J. Clin. Oncol.</source>
  <year>2002</year>
  <volume>20</volume>
  <fpage>274</fpage>
  <lpage>281</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.20.1.274</pub-id>
  <?supplied-pmid 11773179?>
  <pub-id pub-id-type="pmid">11773179</pub-id>
 </element-citation>
</ref>
